about
Metabolic Effects of CX3CR1 Deficiency in Diet-Induced Obese MiceInterferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway.Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.Energy expenditure in obesity associated with craniopharyngioma.Higher plasma CXCL12 levels predict incident myocardial infarction and death in chronic kidney disease: findings from the Chronic Renal Insufficiency Cohort study.Activation of innate immunity modulates insulin sensitivity, glucose effectiveness and pancreatic β-cell function in both African ancestry and European ancestry healthy humansComparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production.Fractalkine is a novel human adipochemokine associated with type 2 diabetesSerum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.Expression of Calgranulin Genes S100A8, S100A9 and S100A12 Is Modulated by n-3 PUFA during Inflammation in Adipose Tissue and Mononuclear CellsA human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial.Adipose genes down-regulated during experimental endotoxemia are also suppressed in obesity.Race and gender variation in response to evoked inflammationGene profiling of human adipose tissue during evoked inflammation in vivo.Differential associations of oral glucose tolerance test-derived measures of insulin sensitivity and pancreatic β-cell function with coronary artery calcification and microalbuminuria in type 2 diabetes.Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers.Inflammation and Adipose DysfunctionIn Reply to ‘Serum Fractalkines and Cardiovascular Outcomes in the CRIC Study Cohort’Fish Oil Derived Omega 3 Fatty Acids Suppress Adipose NLRP3 Inflammasome Signaling in Human ObesityEndocrine-sensitive physical endpoints in newborns: ranges and predictors
P50
Q27317248-043096B2-A0B0-4660-BB55-DFF0DE594ECAQ33553780-7405C4FC-6870-447E-82F1-F8B89074901DQ33556498-FF4D2013-BD92-413E-8C32-7F735EF80824Q33903122-B362B49A-C99F-4D2E-AA1D-EA84873F66F7Q34043983-7FEFF0ED-FC1E-4A09-A310-5676B1DF5061Q35137615-CEBFF352-D7FB-4CE4-B446-5F3F11E3C34EQ35458175-095C95FE-31AA-477A-94A7-1F2FE32B1ACDQ35796996-2EC4CB73-FEB3-447C-902A-611AA63342F3Q35893544-A25338F1-DB11-4698-874A-85C61B1ADE5EQ36261057-A79FDD38-7BFF-4C6F-A6D0-5A5CB4F682A8Q36335205-239F333E-6D8A-4E16-A9C6-03AC2612A40AQ36361395-6952E1AF-BE19-4273-A845-47178F67780FQ36794209-B1E937A4-4DEA-4913-9CB1-2C1C85E105FFQ37360466-25882968-F4F9-4640-9793-7DF4ABABFA4EQ37360466-D0E401F0-660B-4173-982A-87ECBBA3EBE3Q37403198-D47C49AD-2E65-4F19-B0BC-E0285792F498Q37626547-7BAEBB61-EF3A-4043-9C38-D5D63C57C871Q57428290-70600EE2-2FDE-45AC-AA4F-37F54405B2E0Q60654155-16304FB2-E13C-467B-96EF-F28F23091A92Q61813664-72B8FD2E-1904-4698-994E-EDFAA8537445Q94588775-441D7368-1640-4120-A4B8-FF443FD6D3D1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rachana Shah
@ast
Rachana Shah
@en
Rachana Shah
@es
Rachana Shah
@nl
Rachana Shah
@sl
type
label
Rachana Shah
@ast
Rachana Shah
@en
Rachana Shah
@es
Rachana Shah
@nl
Rachana Shah
@sl
prefLabel
Rachana Shah
@ast
Rachana Shah
@en
Rachana Shah
@es
Rachana Shah
@nl
Rachana Shah
@sl
P106
P21
P31
P496
0000-0001-7866-557X